adagrasib Krazati
Selected indexed studies
- Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation. (N Engl J Med, 2022) [PMID:35658005]
- Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer. (Cancer Discov, 2024) [PMID:38587856]
- Adagrasib (Krazati) for colorectal cancer. (Med Lett Drugs Ther, 2024) [PMID:39137178]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Adagrasib. (2012) pubmed
- Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation. (2022) pubmed
- Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer. (2024) pubmed
- Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. (2023) pubmed
- Adagrasib in Advanced Solid Tumors Harboring a KRAS(G12C) Mutation. (2023) pubmed
- Adagrasib: First Approval. (2023) pubmed
- Adagrasib versus docetaxel in KRAS(G12C)-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial. (2025) pubmed
- Adagrasib (Krazati) for colorectal cancer. (2024) pubmed
- Targeting KRAS in cancer. (2024) pubmed
- KRAS mutation: from undruggable to druggable in cancer. (2021) pubmed